Meningioma: International Consortium on Meningiomas consensus review on scientific advances and treatment paradigms for clinicians, researchers, and patients
Neuro-Oncology · 03.10.2024 · 26 (10) · 1742-1780
DOI: 10.1093/neuonc/noae082 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Neuro-Oncology, online erschienen am 02.05.2024. Verfasst von Justin Z Wang und 50 weiteren Autor:innen. Beteiligte Einrichtung: Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Meningeal Neoplasms, Meningioma. Die Arbeit wurde bisher 166-mal zitiert (Crossref) und nennt 430 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Meningiomas are the most common primary intracranial tumors in adults and are increasing in incidence due to the aging population and increased access to neuroimaging. While most exhibit nonmalignant behavior, a subset of meningiomas are biologically aggressive and are associated with treatment resistance, resulting in significant neurologic morbidity and even mortality. In recent years, meaningful advances in our understanding of the biology of these tumors have led to the incorporation of molecular biomarkers into their grading and prognostication. However, unlike other central nervous system (CNS) tumors, a unified molecular taxonomy for meningiomas has not yet been established and remains an overarching goal of the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy-Not Official World Health Organization (cIMPACT-NOW) working group. Additionally, clinical equipoise still remains on how specific meningioma cases and patient populations should be optimally managed. To address these existing gaps, members of the International Consortium on Meningiomas including field-leading experts, have prepared this comprehensive consensus narrative review directed toward clinicians, researchers, and patients. Included in this manuscript are detailed overviews of proposed molecular classifications, novel biomarkers, contemporary treatment strategies, trials on systemic therapies, health-related quality-of-life studies, and management strategies for unique meningioma patient populations. In each section, we discuss the current state of knowledge as well as ongoing clinical and research challenges to road map future directions for further investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
- Division of Neurosurgery, Department of Surgery, University of Toronto, Toronto, Ontario, Canada.
- MacFeeters Hamilton Neuro-Oncology Program, Princess Margaret Cancer Centre, University Health Network and University of Toronto, Toronto, Ontario, Canada.
- Department of Radiation Oncology, Neurological Surgery, and Pathology, University of California San Francisco, San Francisco, California, USA.
- Department of Neuropathology, University Hospital Heidelberg and German Consortium for Translational Cancer Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
- Department of Neurosurgery, Duke University, Durham, North Carolina, USA.
ORCID-Profile: Felix Sahm, Kyle M Walsh, Norbert Galldiks, Jens Schittenhelm, Michael Weller, Kenneth Aldape, Matthias Preusser, Gelareh Zadeh
Förderung
- NCI NIH HHS
Zitieren
APA
Wang, J. Z., Landry, A. P., Raleigh, D. R., Sahm, F., Walsh, K. M., Goldbrunner, R., Yefet, L. S., Tonn, J. C., Gui, C., Ostrom, Q. T., Barnholtz-Sloan, J., Perry, A., Ellenbogen, Y., Hanemann, C. O., Jungwirth, G., Jenkinson, M. D., Tabatabai, G., Mathiesen, T. I., McDermott, M. W., …, & Zadeh, G. (2024). Meningioma: International Consortium on Meningiomas consensus review on scientific advances and treatment paradigms for clinicians, researchers, and patients. Neuro-Oncology, 26(10), 1742-1780. https://doi.org/10.1093/neuonc/noae082
Vancouver
Wang JZ, Landry AP, Raleigh DR, Sahm F, Walsh KM, Goldbrunner R, et al. Meningioma: International Consortium on Meningiomas consensus review on scientific advances and treatment paradigms for clinicians, researchers, and patients. Neuro-Oncology. 2024;26(10):1742-1780. doi:10.1093/neuonc/noae082
BibTeX
@article{Wang2024,
author = {Wang, Justin Z and Landry, Alexander P and Raleigh, David R and Sahm, Felix and Walsh, Kyle M and Goldbrunner, Roland and Yefet, Leeor S and Tonn, Jörg C and Gui, Chloe and Ostrom, Quinn T and Barnholtz-Sloan, Jill and Perry, Arie and Ellenbogen, Yosef and Hanemann, C Oliver and Jungwirth, Gerhard and Jenkinson, Michael D and Tabatabai, Ghazaleh and Mathiesen, Tiit I and McDermott, Michael W and Tatagiba, Marcos and la Fougère, Christian and Maas, Sybren L N and Galldiks, Norbert and Albert, Nathalie L and Brastianos, Priscilla K and Ehret, Felix and Minniti, Giuseppe and Lamszus, Katrin and Ricklefs, Franz L and Schittenhelm, Jens and Drummond, Katharine J and Dunn, Ian F and Pathmanaban, Omar N and Cohen-Gadol, Aaron A and Sulman, Erik P and Tabouret, Emeline and Le Rhun, Emelie and Mawrin, Christian and Moliterno, Jennifer and Weller, Michael and Bi, Wenya Linda and Gao, Andrew and Yip, Stephen and Niyazi, Maximilian and International Consortium on Meningiomas (ICOM), International Consortium on Meningiomas (ICOM) and Aldape, Kenneth and Wen, Patrick Y and Short, Susan and Preusser, Matthias and Nassiri, Farshad and Zadeh, Gelareh},
title = {Meningioma: International Consortium on Meningiomas consensus review on scientific advances and treatment paradigms for clinicians, researchers, and patients},
journal = {Neuro-Oncology},
year = {2024},
volume = {26},
number = {10},
pages = {1742--1780},
doi = {10.1093/neuonc/noae082}
}
EUVIMED